Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1988 1
1995 1
1996 1
1997 2
1998 3
2000 3
2001 2
2002 3
2003 3
2004 2
2005 3
2006 2
2007 6
2008 11
2009 14
2010 17
2011 21
2012 26
2013 22
2014 25
2015 29
2016 29
2017 32
2018 30
2019 40
2020 35
2021 66
2022 74
2023 76
2024 84
2025 86
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

671 results

Results by year

Filters applied: . Clear all
Page 1
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20(+) B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation acros …
PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them t …
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxi …
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the sa …
Vitamin B(12) status in health and disease: a critical review. Diagnosis of deficiency and insufficiency - clinical and laboratory pitfalls.
Sobczyńska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. Sobczyńska-Malefora A, et al. Crit Rev Clin Lab Sci. 2021 Sep;58(6):399-429. doi: 10.1080/10408363.2021.1885339. Epub 2021 Apr 21. Crit Rev Clin Lab Sci. 2021. PMID: 33881359 Free article. Review.
Vitamin B(12) (cobalamin) is an essential cofactor for two metabolic pathways. It is obtained principally from food of animal origin. ...Future directions for diagnostics of B(12) status and health interventions are also discussed....
Vitamin B(12) (cobalamin) is an essential cofactor for two metabolic pathways. It is obtained principally from food of animal origin. …
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
Li T, Hiemstra IH, Chiu C, Oliveri RS, Elliott B, DeMarco D, Salcedo T, Egerod FL, Sasser K, Ahmadi T, Gupta M. Li T, et al. Clin Pharmacol Ther. 2022 Nov;112(5):1108-1119. doi: 10.1002/cpt.2729. Epub 2022 Sep 27. Clin Pharmacol Ther. 2022. PMID: 35996883 Free PMC article.
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion of T cells and killing of malignant B …
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target …
Clinical quiz.
Abolghasemi H, Kavehmanesh Z, Matinzadeh ZK, Amid A, Ahmadi M. Abolghasemi H, et al. J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):229, 243. doi: 10.1097/00005176-200502000-00029. J Pediatr Gastroenterol Nutr. 2005. PMID: 15711419 No abstract available.
Dibromido(2,9-dimethyl-1,10-phenanthroline-κN,N')mercury(II).
Alizadeh R, Heidari A, Ahmadi R, Amani V. Alizadeh R, et al. Acta Crystallogr Sect E Struct Rep Online. 2009 Apr 2;65(Pt 5):m483-4. doi: 10.1107/S1600536809009994. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21583736 Free PMC article.
In the crystal structure, weak inter-molecular C-HBr hydrogen bonds link the mol-ecules into chains along the b axis. There are pi-pi contacts between the phenanthroline rings [centroid-centroid distances = 3.806 (4), 3.819 (4), 3.739 (3), 3.690 (3), 3.619 (4) and 3.674 (3 …
In the crystal structure, weak inter-molecular C-HBr hydrogen bonds link the mol-ecules into chains along the b axis. There are pi-pi …
OPIOID-EXPRESSING B CELLS SILENCE TUMOR-INFILTRATING NOCICEPTOR NEURONS.
Eichwald T, Ahmadi M, Matos AM, Nikpoor AR, Roversi K, Balood M, Obuekwe F, Nilsen ML, Ruffin AT, Pinheiro G, Brabenec L, Rafei M, Vermeer P, Bruno TC, Scheff NN, Talbot S. Eichwald T, et al. Res Sq [Preprint]. 2025 Sep 3:rs.3.rs-7389517. doi: 10.21203/rs.3.rs-7389517/v1. Res Sq. 2025. PMID: 40951290 Free PMC article. Preprint.
We identified B cells as the primary source of N/OFQ and observed that high expression of either Pnoc or Oprl1 correlates with better survival in both melanoma and HNSCC. ...Moreover, we discovered that Ramp1(+) B cells express Pnoc, but this expression is suppresse …
We identified B cells as the primary source of N/OFQ and observed that high expression of either Pnoc or Oprl1 correlates with better …
671 results